ChineseChina UKUK DeutschlandDeutschland FranceFrance РоссияРоссия 한국한국 ไทยไทย Việt NamViệt Nam العربيةالعربية ҚазақстанҚазақстан EspañaEspaña MyanmarMyanmar DaiDai

Linking China’s Premium Healthcare · Serving Global Health Needs

Breaking down language, channel and process barriers in cross-border care — making the best doctors your personal doctors.
300 Grade-A partner hospitals · 3,000+ leading experts · one-stop service across all specialties

One-Stop Medical Care in China

  • International flights · Airport pickup · Nearby hotels
  • Multilingual interpreters · Full medical escort
  • Expert matching · Hospital fast-track
  • Full-cycle treatment · Post-op follow-up
Sign in

Mr. Edward - Myopia of the face

Patient Basic Information Patient: Mr. Edward (Edward Harris) Nationality: Switzerland Diagnosis: Facial Myeloma Diagnostic Hospitals: 0 days of treatment: Targeted treatment + Immunotherapy Accommodation: 31 days Treatment cost: approximately 158918 yuan Treatment effect: Complete alleviation Upon arrival, the International Medical Services Team arranged for the first time multidisciplinary MDT clinics for patients, developed individualized clinical pathways based on the patient's examination reports and physical condition, and provided translation, guidance and on-site services throughout the treatment process. The MD2 team used a comprehensive set of targeted therapeutic+immunotherapies, with the medical team closely monitoring the patient's indicators and dynamic adjustment programs during the treatment process.

After 31 days of systemic treatment and rehabilitation management, the patient's condition gradually improved, and the test indicators returned to normal areas, successfully reaching the hospital standard. Treatment effects were finally completely alleviated. When the patient left the hospital, the medical team developed a detailed return follow-up and rehabilitation plan for him, and continued to monitor the recovery through the remote follow-up system.

'Mr. Liu Edward criticizes the case as a typical case of cross-border suspected seriousness clinical disease. Liu4 is based on a multidisciplinary collaborative mechanism that has developed targeted treatment+immunotherapy for facial myeloma, reflecting the comprehensive strength of Chinese hospitals in the field of suspected diagnostics and a shorthand for the regulation of international visitor medical services.

瑞士,面肌痉挛,上海交通大学医学院附属仁济医院,国际医疗,来华就医,中国医疗